Cargando…

COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn

The immune response to COVID-19 booster vaccinations during pregnancy for mothers and their newborns and the functional response of vaccine-induced antibodies against Omicron variants are not well characterized. We conducted a prospective, multicenter cohort study of participants vaccinated during p...

Descripción completa

Detalles Bibliográficos
Autores principales: Munoz, Flor M., Posavad, Christine M., Richardson, Barbra A., Badell, Martina L., Bunge, Katherine E., Mulligan, Mark J., Parameswaran, Lalitha, Kelly, Clifton W., Olson-Chen, Courtney, Novak, Richard M., Brady, Rebecca C., Pasetti, Marcela F., Defranco, Emily A., Gerber, Jeffrey S., Mallory C. Shriver, Ms., Suthar, Mehul S., Coler, Rhea N., Berube, Bryan J., So Hee Kim, Ms., Piper, Jeanna M., Ashley M. Miller, Ms., Cardemil, Cristina V., Neuzil, Kathleen M., Beigi, Richard H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261713/
https://www.ncbi.nlm.nih.gov/pubmed/37451878
http://dx.doi.org/10.1016/j.vaccine.2023.06.032
Descripción
Sumario:The immune response to COVID-19 booster vaccinations during pregnancy for mothers and their newborns and the functional response of vaccine-induced antibodies against Omicron variants are not well characterized. We conducted a prospective, multicenter cohort study of participants vaccinated during pregnancy with primary or booster mRNA COVID-19 vaccines from July 2021 to January 2022 at 9 academic sites. We determined SARS-CoV-2 binding and live virus and pseudovirus neutralizing antibody (nAb) titers pre- and post-vaccination, and at delivery for both maternal and infant participants. Immune responses to ancestral and Omicron BA.1 SARS-CoV-2 strains were compared between primary and booster vaccine recipients in maternal sera at delivery and in cord blood, after adjusting for days since last vaccination. A total of 240 participants received either Pfizer or Moderna mRNA vaccine during pregnancy (primary 2-dose series:167; booster dose:73). Booster vaccination resulted in significantly higher binding and nAb titers, including to the Omicron BA.1 variant, in maternal serum at delivery and in cord blood compared to a primary 2-dose series (range 0.44 to 0.88 log(10) higher, p<0.0001 for all comparisons). Live virus nAb to Omicron BA.1 were present at delivery in 9% (GMT ID50 12.7) of Pfizer and 22% (GMT ID50 14.7) of Moderna primary series recipients, and in 73% (GMT ID50 60.2) of mRNA boosted participants (p<0.0001), although titers were significantly lower than to the D614G strain. Transplacental antibody transfer was efficient for all regimens with median transfer ratio range: 1.55-1.77 for IgG, 1.00-1.78 for live virus nAb and 1.79-2.36 for pseudovirus nAb. COVID-19 mRNA vaccination during pregnancy elicited robust immune responses in mothers and efficient transplacental antibody transfer to the newborn. A booster dose during pregnancy significantly increased maternal and cord blood binding and neutralizing antibody levels, including against Omicron BA.1. Findings support the use of a booster dose of COVID-19 vaccine during pregnancy.